open access

Vol 24, No 4 (2017)
Review articles — Interventional cardiology
Published online: 2017-06-20
Get Citation

Fractional flow reserve (FFR)-based therapy in patients presenting with acute coronary syndrome: Current data and everyday practice

Grzegorz Zuk, Dariusz Ciecwierz, Natalia Cwalina, Marcin Gruchala, Florim Cuculi
DOI: 10.5603/CJ.a2017.0072
·
Pubmed: 28653314
·
Cardiol J 2017;24(4):426-435.

open access

Vol 24, No 4 (2017)
Review articles — Interventional cardiology
Published online: 2017-06-20

Abstract

Fractional flow reserve (FFR) is an evidence-based diagnostic tool of physiological significance of coronary artery stenosis in patients with stable coronary artery disease (CAD). Due to microvascular dysfunction in acute coronary syndrome (ACS), information obtained from FFR assessment could be less reliable and, thus, its clinical role remains controversial. Indeed, results of currently published studies are essentially discrepant. Only a few randomized clinical trials have been performed showing the efficacy of FFR-guided percutaneous coronary intervention in ACS. Consequently, its role in acute scenarios remains substantially understudied. Herein, is presented the current state of knowledge re­garding FFR use in ACS setting. (Cardiol J 2017; 24, 4: 426–435)

Abstract

Fractional flow reserve (FFR) is an evidence-based diagnostic tool of physiological significance of coronary artery stenosis in patients with stable coronary artery disease (CAD). Due to microvascular dysfunction in acute coronary syndrome (ACS), information obtained from FFR assessment could be less reliable and, thus, its clinical role remains controversial. Indeed, results of currently published studies are essentially discrepant. Only a few randomized clinical trials have been performed showing the efficacy of FFR-guided percutaneous coronary intervention in ACS. Consequently, its role in acute scenarios remains substantially understudied. Herein, is presented the current state of knowledge re­garding FFR use in ACS setting. (Cardiol J 2017; 24, 4: 426–435)

Get Citation

Keywords

fractional flow reserve, acute coronary syndrome, hyperemia, coronary revascularization, microcirculation

About this article
Title

Fractional flow reserve (FFR)-based therapy in patients presenting with acute coronary syndrome: Current data and everyday practice

Journal

Cardiology Journal

Issue

Vol 24, No 4 (2017)

Pages

426-435

Published online

2017-06-20

DOI

10.5603/CJ.a2017.0072

Pubmed

28653314

Bibliographic record

Cardiol J 2017;24(4):426-435.

Keywords

fractional flow reserve
acute coronary syndrome
hyperemia
coronary revascularization
microcirculation

Authors

Grzegorz Zuk
Dariusz Ciecwierz
Natalia Cwalina
Marcin Gruchala
Florim Cuculi

References (57)
  1. Montalescot G, Sechtem U, Achenbach S, et al. Task Force Members, ESC Committee for Practice Guidelines, Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949–3003.
  2. Windecker S, Kolh P, Alfonso F, et al. Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35(37): 2541–2619.
  3. Tonino P, Bruyne BDe, Pijls N, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3): 213–224.
  4. De Bruyne B, Pijls NHJ, Kalesan B, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012; 367(11): 991–1001.
  5. Pijls NH, De Bruyne B. Coronary Pressure. 2nd Ed. Kluwer Academic Publishers, The Netherlands: 2000.
  6. Spaan JAE, Piek JJ, Hoffman JIE, et al. Physiological basis of clinically used coronary hemodynamic indices. Circulation. 2006; 113(3): 446–455.
  7. Pijls NH, van Son JA, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. 1993; 87(4): 1354–1367.
  8. Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994; 331(4): 222–227.
  9. Ragosta M, Powers ER, Samady H, et al. Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction. Am Heart J. 2001; 141(3): 456–462.
  10. Berry C, Layland J, Sood A, et al. Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. Am Heart J. 2013; 166(4): 662–668.e3.
  11. Layland J, Oldroyd KG, Curzen N, et al. FAMOUS–NSTEMI investigators. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J. 2015; 36(2): 100–111.
  12. Cuculi F, De Maria GL, Meier P, et al. Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014; 64(18): 1894–1904.
  13. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994; 89(3): 1013–1022.
  14. Toth G, Hamilos M, Pyxaras S, et al. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. Eur Heart J. 2014; 35(40): 2831–2838.
  15. Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996; 334(26): 1703–1708.
  16. Layland J, Carrick D, Lee M, et al. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv. 2014; 7(6): 581–591.
  17. De Bruyne B, Pijls NHJ, Barbato E, et al. Intracoronary and intravenous adenosine 5'-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation. 2003; 107(14): 1877–1883.
  18. Lim WH, Koo BK, Nam CW, et al. Variability of fractional flow reserve according to the methods of hyperemia induction. Catheter Cardiovasc Interv. 2014; 85(6): 970–976.
  19. Seto AH, Tehrani DM, Bharmal MI, et al. Variations of coronary hemodynamic responses to intravenous adenosine infusion: implications for fractional flow reserve measurements. Catheter Cardiovasc Interv. 2014; 84(3): 416–425.
  20. Echavarria-Pinto M, Petraco R, van de Hoef TP, et al. Fractional flow reserve and minimum Pd/Pa ratio during intravenous adenosine infusion: very similar but not always the same. EuroIntervention. 2016; 11(9): 1013–1019.
  21. Tarkin JM, Nijjer S, Sen S, et al. Hemodynamic response to intravenous adenosine and its effect on fractional flow reserve assessment: results of the Adenosine for the Functional Evaluation of Coronary Stenosis Severity (AFFECTS) study. Circ Cardiovasc Interv. 2013; 6(6): 654–661.
  22. Adjedj J, Toth GG, Johnson NP, et al. Intracoronary Adenosine: Dose-Response Relationship With Hyperemia. JACC Cardiovasc Interv. 2015; 8(11): 1422–1430.
  23. Matsumoto H, Nakatsuma K, Shimada T, et al. Effect of caffeine on intravenous adenosine-induced hyperemia in fractional flow reserve measurement. J Invasive Cardiol. 2014; 26(11): 580–585.
  24. Coli S, Mantovani F, Ferro J, et al. Adenosine-induced severe bronchospasm in a patient without pulmonary disease. Am J Emerg Med. 2012; 30(9): 2082.e3–2082.e5.
  25. van Nunen LX, Lenders GD, Schampaert S, et al. Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement. EuroIntervention. 2015; 11(8): 905–913.
  26. Rudzinski W, Waller AH, Rusovici A, et al. Comparison of efficacy and safety of intracoronary sodium nitroprusside and intravenous adenosine for assessing fractional flow reserve. Catheter Cardiovasc Interv. 2013; 81(3): 540–544.
  27. Jang HJ, Koo BK, Lee HS, et al. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. Eur Heart J. 2013; 34(27): 2055–2062.
  28. Martin-Reyes R, de la Torre Hernandez JM, Franco-Pelaez J, et al. The use of the acute Pd/Pa drop after intracoronary nitroglycerin infusion to rule out significant FFR: CANICA (Can intracoronary nitroglycerin predict fractional flow reserve without adenosine?) multicenter study. Catheter Cardiovasc Interv. 2016; 87(2): 262–269.
  29. Kern M, Deligonul U, Tatineni S, et al. Intravenous adenosine: Continuous infusion and low dose bolus administration for determination of coronary vasodilator reserve in patients with and without coronary artery disease. J Am Coll Cardiol. 1991; 18(3): 718–729.
  30. Ragosta M, Powers ER, Samady H, et al. Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction. Am Heart J. 2001; 141(3): 456–462.
  31. Wyatt HL, Forrester JS, da Luz PL, et al. Functional abnormalities in nonoccluded regions of myocardium after experimental coronary occlusion. Am J Cardiol. 1976; 37(3): 366–372.
  32. Corday E, Kaplan L, Meerbaum S, et al. Consequences of coronary arterial occlusion on remote myocardium: effects of occlusion and reperfusion. Am J Cardiol. 1975; 36(3): 385–394.
  33. Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007; 28(14): 1709–1716.
  34. Van Herck PL, Carlier SG, Claeys MJ, et al. Coronary microvascular dysfunction after myocardial infarction: increased coronary zero flow pressure both in the infarcted and in the remote myocardium is mainly related to left ventricular filling pressure. Heart. 2007; 93(10): 1231–1237.
  35. Gregorini L, Marco J, Kozàkovà M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999; 99(4): 482–490.
  36. Sambuceti G, Marzullo P, Giorgetti A, et al. Global alteration in perfusion response to increasing oxygen consumption in patients with single-vessel coronary artery disease. Circulation. 1994; 90(4): 1696–1705.
  37. Wu JC, Yun JJ, Dione DP, et al. Severe regional ischemia alters coronary flow reserve in the remote perfusion area. J Nucl Cardiol. 2000; 7(1): 43–52.
  38. Pacella JJ, Villanueva FS. Effect of coronary stenosis on adjacent bed flow reserve: assessment of microvascular mechanisms using myocardial contrast echocardiography. Circulation. 2006; 114(18): 1940–1947.
  39. Nichols WW, Nicolini FA, Yang B, et al. Attenuation of coronary flow reserve and myocardial function after temporary subtotal coronary artery occlusion and increased myocardial oxygen demand in dogs. J Am Coll Cardiol. 1994; 24(3): 795–803.
  40. Marques KM, Knaapen P, Boellaard R, et al. Hyperaemic microvascular resistance is not increased in viable myocardium after chronic myocardial infarction. Eur Heart J. 2007; 28(19): 2320–2325.
  41. Kramer CM, Rogers WJ, Theobald TM, et al. Remote noninfarcted region dysfunction soon after first anterior myocardial infarction. A magnetic resonance tagging study. Circulation. 1996; 94(4): 660–666.
  42. Leesar MA, Abdul-Baki T, Akkus NI, et al. Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina. Effect on duration of hospitalization, cost, procedural characteristics, and clinical outcome. J Am Coll Cardiol. 2003; 41(7): 1115–1121.
  43. De Bruyne B, Sarma J. Fractional flow reserve: a review: invasive imaging. Heart. 2008; 94(7): 949–959.
  44. Smits P, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve–guided multivessel angioplasty in myocardial infarction. New Engl J Med. 2017; 376(13): 1234–1244.
  45. Engstrøm T, Kelbæk H, Helqvist S, et al. DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015; 386(9994): 665–671.
  46. Ntalianis A, Sels JW, Davidavicius G, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010; 3(12): 1274–1281.
  47. Layland J, Rauhalammi S, Watkins S, et al. Assessment of Fractional Flow Reserve in Patients With Recent Non-ST-Segment-Elevation Myocardial Infarction: Comparative Study With 3-T Stress Perfusion Cardiac Magnetic Resonance Imaging. Circ Cardiovasc Interv. 2015; 8(8): e002207.
  48. Samady H, Lepper W, Powers ER, et al. Fractional flow reserve of infarct-related arteries identifies reversible defects on noninvasive myocardial perfusion imaging early after myocardial infarction. J Am Coll Cardiol. 2006; 47(11): 2187–2193.
  49. Cuculi F, De Maria GL, Meier P, et al. Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014; 64(18): 1894–1904.
  50. Hakeem A, Edupuganti MM, Almomani A, et al. Long-Term prognosis of deferred acute coronary syndrome lesions based on nonischemic fractional flow reserve. J Am Coll Cardiol. 2016; 68(11): 1181–1191.
  51. Morrow DA. Cardiovascular risk prediction in patients with stable and unstable coronary heart disease. Circulation. 2010; 121(24): 2681–2691.
  52. Mahaffey KW, Wojdyla DM, Pieper KS, et al. Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clin Cardiol. 2014; 37(6): 337–342.
  53. Rodés-Cabau J, Gutiérrez M, Courtis J, et al. Importance of diffuse atherosclerosis in the functional evaluation of coronary stenosis in the proximal-mid segment of a coronary artery by myocardial fractional flow reserve measurements. Am J Cardiol. 2011; 108(4): 483–490.
  54. Ahmed N, Layland J, Carrick D, et al. Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. Int J Cardiol. 2016; 202: 305–310.
  55. White CW, Wright CB, Doty DB, et al. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med. 1984; 310(13): 819–824.
  56. Tonino PAL, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010; 55(25): 2816–2821.
  57. Selby JV, Fireman BH, Lundstrom RJ, et al. Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med. 1996; 335(25): 1888–1896.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl